Biocompatibles and Johnson and Johnson Interventional co-operate on stents
This article was originally published in Clinica
Executive Summary
Johnson & Johnson (US) is to spend £8.3 million ($12.8 million) on a project to develop coated metal stents with UK-based Biocompatibles. The research and licence agreement will unite J&J Interventional Systems' (JJIS) metallic vascular stents with Biocompatibles' non-thrombogenic and drug delivery phosphorylcholine coatings.